
==== Front
Adv Ther
Adv Ther
Advances in Therapy
0741-238X 1865-8652 Springer Healthcare Communications Heidelberg 

100
10.1007/s12325-010-0100-z
Review
Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention
Groothuis Jessie R. GroothuisJ@MedImmune.com 1 Hoopes J. Michael 1 Jessie Val G. Hemming 2 1 grid.418152.bMedImmune, LLC, 1 MedImmune Way, Gaithersburg, MD 20878 USA 
2 grid.265436.00000000104215525Uniformed Services University of Health Sciences, Bethesda, MD USA 
4 2 2011 
4 2 2011 
2011 
28 2 91 109
20 9 2010 © Springer Healthcare 2011This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.Respiratory syncytial virus (RSV) was first described 160 years ago but was not officially recognized as a cause of serious illness in children until the late 1950s. It has been estimated that virtually all children have had at least one RSV infection by their second birthday. RSV is responsible for annual disease outbreaks, usually during a defined winter seasonal period that can vary by community and year. RSV is recognized as the leading cause of hospitalization among young children worldwide. Infants of young chronologic age and children with predisposing factors, such as premature birth, pulmonary disease, or congenital heart disease, are most susceptible to serious illness. Unlike other viruses, immunity to RSV infection is incomplete and short lived, and reinfection is common throughout life. Initial attempts to develop a vaccine in the 1960s met with unexpected and tragic results; many children vaccinated with a formalin-inactivated wild-type virus developed serious pulmonary disease upon subsequent natural infection. Numerous other vaccine technologies have since been studied, including vectored approaches, virus-like particles, DNA vaccines, and live attenuated virus vaccine. As of early 2010, only two companies or institutions had RSV vaccine candidates in early clinical trials, and no vaccine is likely to be licensed for marketing in the immediate future.

Keywords
childrenhistoryimmunoglobulinimmunoprophylaxismonoclonal antibodyrespiratory syncytial virusvaccineissue-copyright-statement© Springer Healthcare 2011
==== Body
This article is published with open access at Springerlink.com
==== Refs
References
1. Hall C.B.   Feigen R.D.  Cherry J.D.   Respiratory syncytial virus Textbook of Pediatric Infectious Diseases 1987 Philadelphia, PA WB Saunders 1653 1675 
2. Hall C.B.   Respiratory syncytial virus and parainfluenza virus N Engl J Med 2001 344 1917 1928 10.1056/NEJM200106213442507 11419430 
3. Hall C.B.  Weinberg G.A.  Iwane M.K.    The burden of respiratory syncytial virus infection in young children N Engl J Med 2009 360 588 598 10.1056/NEJMoa0804877 19196675 
4. Leader S.  Kohlhase K.   Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999 Pediatr Infect Dis J 2002 21 629 632 10.1097/00006454-200207000-00005 12237593 
5. Ruuskanen O.  Ogra P.L.   Respiratory syncytial virus Curr Probl Pediatr 1993 23 50 79 10.1016/0045-9380(93)90003-U 7681743 
6. Shay D.K.  Holman R.C.  Newman R.D.  Liu L.L.  Stout J.W.  Anderson L.J.   Bronchiolitis-associated hospitalizations among US children, 1980–1996 JAMA 1999 282 1440 1446 10.1001/jama.282.15.1440 10535434 
7. Leader S.  Kohlhase K.   Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000 J Pediatr 2003 143 S127 132 14615711 
8. McLaurin K, Leader S. Growing impact of RSV hospitalizations among infants in the US, 1997–2002. Paper presented at: Pediatric Academic Societies’ Meeting; May 14–17, 2005; Washington, DC, USA.
9. Nair H.  Nokes D.J.  Gessner B.D.    Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 2010 375 1545 1555 10.1016/S0140-6736(10)60206-1 20399493 
10. Carroll K.N.  Gebretsadik T.  Griffin M.R.    Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan Pediatrics 2008 122 58 64 10.1542/peds.2007-2087 18595987 
11. Forbes M.L.  Hall C.B.  Jackson A.  Masaquel A.S.  Mahadevia P.J.   Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life J Med Econ 2010 13 136 141 10.3111/13696990903583404 20128663 
12. Ruotsalainen M.  Piippo-Savolainen E.  Hyvarinen M.K.  Korppi M.   Respiratory morbidity in adulthood after respiratory syncytial virus hospitalization in infancy Pediatr Infect Dis J 2010 29 872 874 10.1097/INF.0b013e3181dea5de 20803817 
13. Stein R.T.  Sherrill D.  Morgan W.J.    Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years Lancet 1999 354 541 545 10.1016/S0140-6736(98)10321-5 10470697 
14. Sigurs N.  Aljassim F.  Kjellman B.    Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life Thorax 2010 65 1045 1052 10.1136/thx.2009.121582 20581410 
15. Eberle J.   A Treatise on the Diseases and Physical Education of Children 1850 Philadelphia, PA Lippincott, Grambo and Co. 
16. Adams J.M.   Primary virus pneumonitis with cytoplasmic inclusion bodies: study of an epidemic involving thirty-two infants, with nine deaths JAMA 1941 116 925 933 
17. Adams J.M.  Green R.G.  Evans C.A.  Northrop B.   Primary virus pneumonitis: a comparative study of two epidemics J Pediatr 1942 20 405 420 10.1016/S0022-3476(42)80256-5 
18. Blount R.E. Jr  Morris J.A.  Savage R.E.   Recovery of cytopathogenic agent from chimpanzees with coryza Proc Soc Exp Biol Med 1956 92 544 549 13359460 
19. Chanock R.  Finberg L.   Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children Am J Hyg 1957 66 291 300 13478579 
20. Chanock R.  Roizman B.  Myers R.   Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization Am J Hyg 1957 66 281 290 13478578 
21. Chin J.  Magoffin R.L.  Shearer L.A.  Schieble J.H.  Lennette E.H.   Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population Am J Epidemiol 1969 89 449 463 4305200 
22. Fulginiti V.A.  Eller J.J.  Sieber O.F.  Joyner J.W.  Minamitani M.  Meiklejohn G.   Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine Am J Epidemiol 1969 89 435 448 4305199 
23. Kapikian A.Z.  Mitchell R.H.  Chanock R.M.  Shvedoff R.A.  Stewart C.E.   An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine Am J Epidemiol 1969 89 405 421 4305197 
24. Kim H.W.  Canchola J.G.  Brandt C.D.    Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine Am J Epidemiol 1969 89 422 434 4305198 
25. Dreizin R.S.  Vyshnevetskaia L.O.  Bagdamian E.E.  Iankevich O.D.  Tarasova L.B.   Experimental RS virus infection of cotton rats. A viral and immunofluorescent study [in Russian] Vopr Virusol 1971 16 670 676 5141611 
26. Prince G.A.  Jenson A.B.  Horswood R.L.  Camargo E.  Chanock R.M.   The pathogenesis of respiratory syncytial virus infection in cotton rats Am J Pathol 1978 93 771 791 362946 
27. Prince G.A.  Horswood R.L.  Camargo E.  Koenig D.  Chanock R.M.   Mechanisms of immunity to respiratory syncytial virus in cotton rats Infect Immun 1983 42 81 87 6352505 
28. Belshe R.B.  Van Voris L.P.  Mufson M.A.   Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial J Infect Dis 1982 145 311 319 10.1093/infdis/145.3.311 7037983 
29. Hemming V.G.  Rodriguez W.  Kim H.W.    Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children Antimicrob Agents Chemother 1987 31 1882 1886 3439796 
30. Groothuis J.R.  Levin M.J.  Rodriguez W.    Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics The RSVIG Study Group. Antimicrob Agents Chemother 1991 35 1469 1473 
31. Meissner H.C.  Fulton D.R.  Groothuis J.R.    Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin Antimicrob Agents Chemother 1993 37 1655 1658 8215279 
32. Belshe R.B.  Anderson E.L.  Walsh E.E.   Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children J Infect Dis 1993 168 1024 1029 10.1093/infdis/168.4.1024 8376814 
33. Tristram D.A.  Welliver R.C.  Mohar C.K.  Hogerman D.A.  Hildreth S.W.  Paradiso P.   Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old J Infect Dis 1993 167 191 195 10.1093/infdis/167.1.191 8418166 
34. Falsey A.R.  Walsh E.E.   Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60 Vaccine 1996 14 1214 1218 10.1016/S0264-410X(96)00030-8 8961507 
35. Groothuis J.R.  King S.J.  Hogerman D.A.  Paradiso P.R.  Simoes E.A.   Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia J Infect Dis 1998 177 467 469 10.1086/517377 9466539 
36. Piedra P.A.  Grace S.  Jewell A.    Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis Pediatr Infect Dis J 1998 17 217 224 10.1097/00006454-199803000-00009 9535249 
37. Power U.F.  Nguyen T.N.  Rietveld E.    Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults J Infect Dis 2001 184 1456 1460 10.1086/324426 11709789 
38. Munoz F.M.  Piedra P.A.  Glezen W.P.   Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women Vaccine 2003 21 3465 3467 10.1016/S0264-410X(03)00352-9 12850361 
39. Groothuis J.R.  Simoes E.A.  Levin M.J.    Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group N Engl J Med 1993 329 1524 1530 10.1056/NEJM199311183292102 8413475 
40. The PREVENT Study Group.  Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis Pediatrics 1997 99 93 99 10.1542/peds.99.1.93 8989345 
41. Simoes E.A.  Sondheimer H.M.  Top F.H. Jr    Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease The Cardiac Study Group. J Pediatr 1998 133 492 499 
42. The IMpact-RSV Study Group.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants Pediatrics 1998 102 531 537 10.1542/peds.102.3.531 
43. OraVax Reports Results from Phase III Trial of HNK20.  Nosedrop for Respiratory Syncytial Virus in Infants [press release] 1997 Cambridge (MA) OraVax 
44. Meissner H.C.  Groothuis J.R.  Rodriguez W.J.    Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease Antimicrob Agents Chemother 1999 43 1183 1188 10223933 
45. Rodriguez W.J.  Gruber W.C.  Welliver R.C.    Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group Pediatrics 1997 99 454 461 10.1542/peds.99.3.454 9041304 
46. Feltes T.F.  Cabalka A.K.  Meissner H.C.    Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease J Pediatr 2003 143 532 540 10.1067/S0022-3476(03)00454-2 14571236 
47. Carbonell-Estrany X.  Simoes E.A.  Dagan R.    Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial Pediatrics 2010 125 e35 51 10.1542/peds.2008-1036 20008423 
48. Feltes TF, Sondheimer HM, Harris BS, et al. A randomized controlled trial of RSV prophylaxis with motavizumab vs palivizumab in young children with hemodynamically significant congenital heart disease (CHD). Paper presented at: Pediatric Academic Societies Annual Meeting; May 1–4, 2010; Vancouver, BC, Canada.
49. Chandran A, Millar EV, Weatherholtz R, et al. Safety and efficacy of motavizumab in the prevention of RSV disease in healthy infants. Paper presented at: American Pediatric Society/77th Annual Meeting for the Society for Pediatric Research; May 4, 2008; Honolulu, HI, USA.
50. Beem M.  Wright F.H.  Hamre D.  Egerer R.  Oehme M.   Association of the chimpanzee coryza agent with acute respiratory disease in children N Engl J Med 1960 263 523 530 10.1056/NEJM196009152631101 13798226 
51. Chanock R.M.  Kim H.W.  Vargosko A.J.    Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children JAMA 1961 176 647 653 13692354 
52. Parrott R.H.  Vargosko A.J.  Kim H.W.    Respiratory syncytial virus. II. Serologic studies over a 34-month period of children with bronchiolitis, pneumonia, and minor respiratory diseases JAMA 1961 176 653 657 13732993 
53. Adams J.M.  Imagawa D.T.  Zike K.   Epidemic bronchiolitis and pneumonitis related to respiratory syncytial virus JAMA 1961 176 1037 1039 13681401 
54. Hamparian V.V.  Ketler A.  Hilleman M.R.    Studies of acute respiratory illnesses caused by respiratory syncytial virus. 1. Laboratory findings in 109 cases Proc Soc Exp Biol Med 1961 106 717 722 13711106 
55. Kapikian A.Z.  Bell J.A.  Mastrota F.M.  Johnson K.M.  Huebner R.J.  Chanock R.M.   An outbreak of febrile illness and pneumonia associated with respiratory syncytial virus infection Am J Hyg 1961 74 234 248 14453700 
56. Peacock D.B.  Clarke S.K.   Respiratory syncytial virus in Britain Lancet 1961 ii 466 10.1016/S0140-6736(61)92435-7 
57. Rowe D.S.  Michaels R.H.   Isolation of the respiratory syncytial virus from a patient with pneumonia Pediatrics 1960 26 623 629 13744117 
58. Chanock R.M.  Parrott R.H.  Vargosko A.J.  Kapikian A.Z.  Knight V.  Johnson K.M.   Acute respiratory diseases of viral etiology. IV. Respiratory syncytial virus Am J Public Health Nations Health 1962 52 918 925 10.2105/AJPH.52.6.918 13878129 
59. Beem M.   Repeated infections with respiratory syncytial virus J Immunol 1967 98 1115 1122 4290804 
60. Glezen W.P.  Taber L.H.  Frank A.L.  Kasel J.A.   Risk of primary infection and reinfection with respiratory syncytial virus Am J Dis Child 1986 140 543 546 3706232 
61. Hall C.B.  Walsh E.E.  Long C.E.  Schnabel K.C.   Immunity to and frequency of reinfection with respiratory syncytial virus J Infect Dis 1991 163 693 698 10.1093/infdis/163.4.693 2010624 
62. Henderson F.W.  Collier A.M.  Clyde W.A. Jr  Denny F.W.   Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children N Engl J Med 1979 300 530 534 10.1056/NEJM197903083001004 763253 
63. Bruhn F.W.  Yeager A.S.   Respiratory syncytial virus in early infancy. Circulating antibody and the severity of infection Am J Dis Child 1977 131 145 148 835529 
64. Kasel J.A.  Walsh E.E.  Frank A.L.  Baxter B.D.  Taber L.H.  Glezen W.P.   Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children Viral Immunol 1987 1 199 205 10.1089/vim.1987.1.199 3509676 
65. Lamprecht C.L.  Krause H.E.  Mufson M.A.   Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus J Infect Dis 1976 134 211 217 10.1093/infdis/134.3.211 977992 
66. Ogilvie M.M.  Vathenen A.S.  Radford M.  Codd J.  Key S.   Maternal antibody and respiratory syncytial virus infection in infancy J Med Virol 1981 7 263 271 10.1002/jmv.1890070403 7038043 
67. Parrott R.H.  Kim H.W.  Arrobio J.O.    Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex Am J Epidemiol 1973 98 289 300 4355170 
68. Welliver R.C.   Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection J Pediatr 2003 143 S112 117 10.1067/S0022-3476(03)00508-0 14615709 
69. Committee on Infectious Diseases.  Modified 69. recommendations for use of palivizumab for prevention of respiratory syncytial virus infections Pediatrics 2009 124 1694 1701 10.1542/peds.2009-2345 19736258 
70. Makari D.  Groothuis J.   Health risks of the late-preterm infant Neonatol Today 2009 4 1 8 10.1016/j.nantod.2008.10.016 
71. Engle W.A.  Tomashek K.M.  Wallman C.   “Late-71. preterm” infants: a population at risk Pediatrics 2007 120 1390 1401 10.1542/peds.2007-2952 18055691 
72. Boyce T.G.  Mellen B.G.  Mitchel E.F. Jr  Wright P.F.  Griffin M.R.   Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid J Pediatr 2000 137 865 870 10.1067/mpd.2000.110531 11113845 
73. Colin A.A.  McEvoy C.  Castile R.   Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks’ gestational age Pediatrics 2010 126 115 128 10.1542/peds.2009-1381 20530073 
74. Law B.J.  MacDonald N.  Langley J.    Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent? Paediatr Child Health. 1998 3 402 404 20401222 
75. Willson D.F.  Landrigan C.P.  Horn S.D.  Smout R.J.   Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia J Pediatr 2003 143 S142 149 10.1067/S0022-3476(03)00514-6 14615713 
76. Groothuis J.R.  Gutierrez K.M.  Lauer B.A.   Respiratory syncytial virus infection in children with bronchopulmonary dysplasia Pediatrics 1988 82 199 203 3399292 
77. MacDonald N.E.  Hall C.B.  Suffin S.C.  Alexson C.  Harris P.J.  Manning J.A.   Respiratory syncytial viral infection in infants with congenital heart disease N Engl J Med 1982 307 397 400 10.1056/NEJM198208123070702 7088112 
78. Navas L.  Wang E.  de Carvalho V.  Robinson J.   Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada J Pediatr 1992 121 348 354 10.1016/S0022-3476(05)90000-0 1517907 
79. Panitch H.B.   Viral respiratory infections in children with technology dependence and neuromuscular disorders Pediatr Infect Dis J 2004 23 S222 227 10.1097/01.inf.0000144670.78558.c7 15577577 
80. Wilkesmann A.  Ammann R.A.  Schildgen O.    Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course Pediatr Infect Dis J 2007 26 485 491 10.1097/INF.0b013e31805d01e3 17529864 
81. Carbonell-Estrany X.  Quero J.   Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons Pediatr Infect Dis J 2001 20 874 879 10.1097/00006454-200109000-00010 11734767 
82. Figueras-Aloy J.  Carbonell-Estrany X.  Quero J.   Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain Pediatr Infect Dis J 2004 23 815 820 10.1097/01.inf.0000136869.21397.6b 15361718 
83. Simoes E.A.   Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease J Pediatr 2003 143 S118 126 10.1067/S0022-3476(03)00511-0 14615710 
84. McConnochie K.M.  Roghmann K.J.   Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis Am J Dis Child 1986 140 806 812 3728410 
85. von Linstow M.L.  Hogh M.  Nordbo S.A.  Eugen-Olsen J.  Koch A.  Hogh B.   A community study of clinical traits and risk factors for human metapneumovirus and respiratory syncytial virus infection during the first year of life Eur J Pediatr 2008 167 1125 1133 10.1007/s00431-007-0643-4 18172683 
86. Lanari M.  Giovannini M.  Giuffre L.    Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity Pediatr Pulmonol 2002 33 458 465 10.1002/ppul.10047 12001280 
87. Resch B.  Manzoni P.  Lanari M.   Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes Paediatr Respir Rev 2009 10 148 153 10.1016/j.prrv.2009.06.003 19651386 
88. Resch B.  Pasnocht A.  Gusenleitner W.  Muller W.   Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29–36 weeks gestational age J Infect 2005 50 397 403 10.1016/j.jinf.2004.06.015 15907547 
89. Simoes E.A.  King S.J.  Lehr M.V.  Groothuis J.R.   Preterm twins and triplets. A high-risk group for severe respiratory syncytial virus infection Am J Dis Child 1993 147 303 306 8438813 
90. Collins P.L.  Graham B.S.   Viral and host factors in human respiratory syncytial virus pathogenesis J Virol 2008 82 2040 2055 10.1128/JVI.01625-07 17928346 
91. Yeung C.Y.  Hobbs J.R.   Serum-gamma-G-globulin levels in normal premature, post-mature, and “small-for-dates” newborn babies Lancet 1968 i 1167 1170 10.1016/S0140-6736(68)91865-5 
92. Ballow M.  Cates K.L.  Rowe J.C.  Goetz C.  Desbonnet C.   Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections Pediatr Res 1986 20 899 904 10.1203/00006450-198609000-00019 3748663 
93. Brandenburg A.H.  Groen J.  van Steensel-Moll H.A.    Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection J Med Virol 1997 52 97 104 10.1002/(SICI)1096-9071(199705)52:1<97::AID-JMV16>3.0.CO;2-Y 9131465 
94. Hacimustafaoglu M.  Celebi S.  Aynaci E.    The progression of maternal RSV antibodies in the offspring Arch Dis Child 2004 89 52 53 10.1136/adc.2002.017780 14709507 
95. Ochola R.  Sande C.  Fegan G.    The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya PLoS ONE 2009 4 e8088 10.1371/journal.pone.0008088 19956576 
96. Murphy B.R.  Alling D.W.  Snyder M.H.    Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection J Clin Microbiol 1986 24 894 898 3771779 
97. Murphy B.R.  Prince G.A.  Walsh E.E.    Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine J Clin Microbiol 1986 24 197 202 3755730 
98. Murphy B.R.  Walsh E.E.   Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity J Clin Microbiol 1988 26 1595 1597 2459154 
99. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum Vaccin. 2010;6.
100. Castilow E.M.  Varga S.M.   Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination Future Virol 2008 3 445 454 10.2217/17460794.3.5.445 19057653 
101. Delgado M.F.  Coviello S.  Monsalvo A.C.    Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease Nat Med 2009 15 34 41 10.1038/nm.1894 19079256 
102. Haynes L.M.  Jones L.P.  Barskey A.  Anderson L.J.  Tripp R.A.   Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P J Virol 2003 77 9831 9844 10.1128/JVI.77.18.9831-9844.2003 12941892 
103. Johnson T.R.  Teng M.N.  Collins P.L.  Graham B.S.   Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV J Virol 2004 78 6024 6032 10.1128/JVI.78.11.6024-6032.2004 15141000 
104. Ponnuraj E.M.  Hayward A.R.  Raj A.  Wilson H.  Simoes E.A.   Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata ) pre-immunized with a formalin-inactivated RSV vaccine J Gen Virol 2001 82 2663 2674 11602778 
105. Prince G.A.  Curtis S.J.  Yim K.C.  Porter D.D.   Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine J Gen Virol 2001 82 2881 2888 11714962 
106. Prince G.A.  Jenson A.B.  Hemming V.G.    Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus J Virol 1986 57 721 728 2419587 
107. Sparer T.E.  Matthews S.  Hussell T.    Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia J Exp Med 1998 187 1921 1926 10.1084/jem.187.11.1921 9607931 
108. Stevens W.W.  Sun J.  Castillo J.P.  Braciale T.J.   Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease Viral Immunol 2009 22 243 251 10.1089/vim.2009.0016 19594395 
109. Englund J.   In search of a vaccine for respiratory syncytial virus: the saga continues J Infect Dis 2005 191 1036 1039 10.1086/427998 15747236 
110. Dudas R.A.  Karron R.A.   Respiratory syncytial virus vaccines Clin Microbiol Rev 1998 11 430 439 9665976 
111. Durbin A.P.  Karron R.A.   Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines Clin Infect Dis 2003 37 1668 1677 10.1086/379775 14689350 
112. Kneyber M.C.  Kimpen J.L.   Advances in respiratory syncytial virus vaccine development Curr Opin Investig Drugs 2004 5 163 170 15043390 
113. van Drunen Littel-van den Hurk S.  Mapletoft J.W.  Arsic N.  Kovacs-Nolan J.   Immunopathology of RSV infection: prospects for developing vaccines without this complication Rev Med Virol 2007 17 5 34 10.1002/rmv.518 17004293 
114. Schickli J.H.  Dubovsky F.  Tang R.S.   Challenges in developing a pediatric RSV vaccine Hum Vaccin 2009 5 582 591 19556888 
115. Power U.F.   Respiratory syncytial virus (RSV) vaccines—two steps back for one leap forward J Clin Virol 2008 41 38 44 10.1016/j.jcv.2007.10.024 18340669 
116. Clyde W.A. Jr   Experimental models for study of common respiratory viruses Environ Health Perspect 1980 35 107 112 10.1289/ehp.8035107 6250807 
117. Coates H.V.  Chanock R.M.   Experimental infection with respiratory syncytial virus in several species of animals Am J Hyg 1962 76 302 312 14021817 
118. Prince G.A.  Porter D.D.   The pathogenesis of respiratory syncytial virus infection in infant ferrets Am J Pathol 1976 82 339 352 1251889 
119. Prince G.A.  Horswood R.L.  Chanock R.M.   Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats J Virol 1985 55 517 520 4020957 
120. Siber G.R.  Leombruno D.  Leszczynski J.    Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin J Infect Dis 1994 169 1368 1373 10.1093/infdis/169.6.1368 8195619

